The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors(University Medical Center Groningen), Piotr Ponikowski(Wroclaw Medical University), Róbert Gábor Kiss, Martina Brueckmann, John R. Teerlink(University of Glasgow), Michael Fu(Rutgers, The State University of New Jersey), Maurizio Volterrani(Vita-Salute San Raffaele University), Mitchell A. Psotka(Alaska Heart and Vascular Institute), Morten Schou(British Heart Foundation), Henrik Schirmer(ESCP Business School), Yasushi Sakata(Osaka University), Mikhail Kosiborod(AstraZeneca (Brazil)), Lenka Špinarová(Masaryk University), Sean P. Collins(Wayne State University), Jerzy Krzysztof Wranicz(Medical University of Lodz), Stefan Janssens(Maastricht University), Robert J. Mentz(Duke University), Jasper Tromp(Duke-NUS Medical School), Afshin Salsali(Rutgers, The State University of New Jersey), Christiane E. Angermann(Universitätsklinikum Würzburg), Jan Biegus(Wroclaw Medical University), Jon Blatchford(Boehringer Ingelheim (United Kingdom)), Shelley Zieroth(University of Manitoba), J COMINCOLET(Bellvitge University Hospital), Uwe Zeymer(University of Freiburg), Michael E. Nassif(Saint Luke's Health System), João Pedro Ferreira(Inserm), P. Christian Schulze(Temple College), C. Jan Willem Borleffs(Haga Hospital), Changsheng Ma(Second Hospital of Shandong University)
Nature Medicine
February 28, 2022
Cited by 889


Related Papers